Seeking Alpha

Johnson & Johnson (JNJ)

  • Jan. 22, 2013, 7:47 AM
    Johnson & Johnson (JNJ): Q4 EPS of $1.19 beats by $0.02. Revenue of $17.6B (+8% Y/Y) misses by $0.07B. Shares -1.3% premarket. (PR)
    | Comment!
  • Jan. 22, 2013, 12:04 AM
    Notable earnings before Tuesday’s open: AMTD, CNI, CRBC, DAL, DD, EAT, FCX, FMER, JNJ, KSU, MTG, PETS, RF, SNV, TRV, VZ, WAT
    | Comment!
  • Jan. 18, 2013, 2:56 PM
    Johnson & Johnson (JNJ) has reportedly offered to pay more than $200k per hip case, for a settlement that would top $2B. Johnson & Johnson (JNJ -0.2%) and Zimmer Holding (ZMH -1.8%) have been the subject of thousands of patient lawsuits for their metal-on-metal hip implants, which have been linked to almost 16,800 adverse events in the U.S. between 2000 and 2011.
  • Jan. 17, 2013, 7:44 PM
    The FDA is concerned whether several medical devices already on the market, such as electroconvulsive therapy devices for depression and emergency defibrillators, require additional evidence to prove they're safe. It's issued a safety advisory, saying patients with symptoms suggesting their devices aren't functioning properly should be considered for testing of possible metal ions in their bloodstream. Symptoms include: skin rashes, neurological changes such as hearing and vision impairment, and psychological status changes including depression.
    | Comment!
  • Jan. 11, 2013, 5:52 AM
    An FDA advisory committee yesterday voted 10 to 5 to recommend approving Johnson & Johnson's (JNJ) canagliflozin treatment for Type 2 diabetes, although several of the panelists expressed concerns about its cardiovascular risks and its use for patients with moderate kidney disease. If authorized, analysts have forecast that canagliflozin could generate annual sales of $667M by 2016.
    | Comment!
  • Jan. 8, 2013, 10:24 AM
    The FDA says Johnson & Johnson's (JNJ +0.1%) diabetes drug Invokana was effective at lowering a key measure of blood sugar, but the agency raised concerns about potential stroke and bone-related safety risks. The drug is due to be reviewed on Thursday by the FDA's endocrinologic and metabolic drugs advisory committee, which is made up of non-FDA medical experts. The agency released its review of the product today in preparation for the panel meeting.
    | Comment!
  • Jan. 7, 2013, 4:33 AM
    Jury selection is due to begin today in the first trial over Johnson & Johnson's (JNJ) Gynecare Prolift vaginal mesh implant, which a South Dakota woman says has caused her constant pain and has led to 18 operations. The complaint is one of 1,800 against Prolift, which J&J has said it will stop selling, while other manufacturers of similar implants also face lawsuits. (previous)
    | Comment!
  • Jan. 4, 2013, 9:04 AM
    Johnson & Johnson (JNJ) is raised to Buy from Hold with an $82 price target, up from $75, at Deutsche Bank, which cites improving sales trends and benefits of diversification. Recent and new drugs should continue to drive pharma sales, and JNJ should continue to work through the McNeil Consent Decree and return consumer products to market. JNJ +0.6% premarket.
    | 1 Comment
  • Jan. 3, 2013, 5:08 PM
    Abbott Labs (ABT), Johnson & Johnson (JNJ) and Sanofi (SNY) have all displayed an interest in Warburg Pincus' Bausch & Lomb. Warburg, working through Goldman Sachs (GS), is hoping to get at least $10B for the business and is seeking first-round bids by month’s end. The $10B price tag would be a major coup for Warburg, raking in a 200% return off its $1.7b equity investment.
    | 1 Comment
  • Jan. 3, 2013, 11:43 AM
    Maybe less entertaining than Byron Wien, but almost surely more actionable is this list of predictions for 2013 from Ploutos. Among the ideas is outperformance by DELL and HPQ thanks to activist investors taking major stakes. A big purchase by Berkshire Hathaway (BRK.B) is being talked about, and Ploutos guesses it will be Cummins (CMI). Will JNJ give up its AAA rating to lever up and return cash to shareholders?
  • Jan. 2, 2013, 12:23 PM
    Johnson & Johnson (JNJ) declares $0.61/share quarterly dividend, in line with previous. Forward yield 3.46%. For shareholders of record Feb. 26. Payable Mar. 12. Ex-div date Feb. 22. (PR)
    | Comment!
  • Dec. 31, 2012, 9:41 AM
    The FDA OKs J&J's (JNJ -0.2%) Sirturo drug for treating tuberculosis in patients who don't respond to other medicines. Sirturo is the first drug in four decades to fight TB using a new mechanism - the treatment blocks an enzyme that's vital for the survival of TB bacteria. The FDA authorization comes after only Phase II of trials - J&J is due to start Phase III in Q1 2013 - and despite more patients dying than with other drugs.
    | Comment!
  • Dec. 19, 2012, 8:03 PM
    Shares of Vivus (VVUS) are active in the post session on speculation that Johnson & Johnson (JNJ) and AstraZeneca (AZN) are considering a takeover of the drug developer due to the company's obesity drug Qsymia. Pfizer (PFE) may also take an interest should VVUS come under takeover attack, because obestity drugs are a hot item at present - with over 78M obese adults in the U.S. alone. Deal-watchers are skeptical however, noting that any deal with a chance of success would need to be in the $30-plus per share range. VVUS +1.3% AH.
    | 1 Comment
  • Dec. 19, 2012, 7:25 PM
    The FDA says that the blood thinner Pradaxa is not safe for use on patients with mechanical heart valves. A clinical trial in Europe was recently stopped because users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of the anticoagulant warfarin. There was also more bleeding after valve surgery in Pradaxa users than in warfarin users. Pradaxa's competitors include: Eliquis, from Bristol-Myers Squibb (BMY) and Pfizer (PFE), Xarelto from Johnson & Johnson (JNJ) and Coumadin, an older drug that's also from BMY.
  • Dec. 18, 2012, 6:15 PM
    The top 10 dividend-yielding stocks from the "ultimate stock pickers" at Morningstar: GSK, COP, INTC, LLY, NVS, MRK, PM, PFE, SYY, JNJ.
  • Dec. 15, 2012, 10:30 AM
    After a stretch in which it alienated the infinitely patient Warren Buffett, Johnson & Johnson (JNJ) may be poised for strong performance, writes Andrew Bary. While the Oracle was selling, the Street was starting to warm up to the company. Revenue growth is improving, and the dividend - the stock yields 3.45% - should continue to grow at 8% annually for years. Underweight institutional investors might soon find themselves needing to buy.
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.